GLP1R and type 2 diabetes mellitus: Background/Objectives: Despite the established cardiovascular benefit of sodium–glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs), these medications are under-prescribed in patients with type 2 diabetes.